128,062 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by First Trust Advisors LP

First Trust Advisors LP bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 128,062 shares of the company's stock, valued at approximately $6,856,000. First Trust Advisors LP owned 0.24% of Janux Therapeutics as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Lester Murray Antman dba SimplyRich raised its holdings in Janux Therapeutics by 205.3% in the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock valued at $1,301,000 after buying an additional 16,351 shares during the period. abrdn plc acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $3,430,000. Barclays PLC boosted its position in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc increased its holdings in Janux Therapeutics by 45.3% in the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock valued at $1,849,000 after purchasing an additional 10,776 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after purchasing an additional 599 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Stock Down 8.3 %

NASDAQ JANX traded down $2.73 on Monday, hitting $30.15. 518,286 shares of the stock were exchanged, compared to its average volume of 846,392. Janux Therapeutics, Inc. has a fifty-two week low of $22.52 and a fifty-two week high of $71.71. The company has a 50-day moving average price of $29.80 and a 200-day moving average price of $42.47. The company has a market cap of $1.78 billion, a PE ratio of -25.85 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock worth $313,964 over the last 90 days. 29.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

JANX has been the subject of several research analyst reports. Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, Wedbush reissued an "outperform" rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.